Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
20
3
2021
medline:
14
9
2021
entrez:
19
3
2021
Statut:
ppublish
Résumé
Lymph nodes (LNs) involved by a myelodysplastic syndrome (MDS) are rare and uncommonly biopsied. In this study, we report 6 MDS patients who underwent an LN biopsy that showed MDS, and we summarize the clinicopathologic features of this cohort. All patients presented with lymphadenopathy (generalized in 5), 5 patients had splenomegaly, and 3 patients had hepatomegaly. Histologically, the LN architecture was distorted without complete effacement. MDS cells, mostly of the myeloid lineage, produced interfollicular expansion. These myeloid cells exhibited a spectrum of maturation, and immature and atypical forms were common, including eosinophils. Scattered megakaryocytes and nucleated erythroid cells were often present. Concurrent bone marrow aspirate and biopsy specimens in these patients showed persistent/resistant MDS. Following the diagnosis of LN involvement, patients did not respond well to therapy and all died by the time of the last follow-up, with a median survival of 6.7 months (range, 4.5 to 21.6 mo). In summary, patients with MDS uncommonly develop clinically evident lymphadenopathy prompting biopsy as a result of infiltration by MDS. MDS in LNs can be subtle, showing incomplete and sometimes mild distortion of the architecture, and ancillary studies including immunohistochemical and flow cytometric immunophenotypic analysis are often needed to establish the diagnosis. These data also suggest that the emergence of lymphadenopathy attributable to MDS is associated with poor treatment response and prognosis in MDS patients and that aggressive therapy or alternative treatment regimens need to be explored in this context.
Identifiants
pubmed: 33739784
pii: 00000478-202107000-00006
doi: 10.1097/PAS.0000000000001689
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
930-938Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Hasserjian RP, Orazi A, Brunning RD, et al. Swerdlow SH, Campo E, Harris NL. Myelodysplastic syndromes: overview. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2017:98–106.
Byrd JC, Edenfield WJ, Dow NS, et al. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Leuk Lymphoma. 1996;21:153–159.
List AF, Gonzalez-Osete G, Kummet T, et al. Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am J Med. 1991;90:274–276.
Nielsen B, Hansen S, Thiede T. Myeloid lymphoid node infiltration preceding acute myeloid leukaemia in a case of myelodysplastic syndrome. Br J Haematol. 1983;54:321–323.
Fulciniti F, Zeppa P, Marino G, et al. Lymphnode localization of extramedullary myeloid cell tumor in myelodysplastic syndrome: report of one case diagnosed by fine-needle cytology. Diagn Cytopathol. 2003;28:136–139.
Thiele J, Kvasnicka HM, Orazi A, et al. Swerdlow SH, Campo E, Harris NL. Primary myelofibrosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2017:44–50.
Khoury JD, Wang WL, Prieto VG, et al. Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial. Clin Cancer Res. 2018;24:521–531.
Hu Z, Wang W, Thakral B, et al. Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution. Cytometry B Clin Cytom. 2020. [Epub ahead of print].
Tang G, Hu S, Wang SA, et al. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J Mol Diagn. 2019;21:343–351.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29:1963–1970.
Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120:1398–1408.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29:854–864.
Patel KP, Ruiz-Cordero R, Chen W, et al. Ultra-rapid reporting of GENomic Targets (URGENTseq): clinical next-generation sequencing results within 48 hours of sample collection. J Mol Diagn. 2019;21:89–98.
Roth MJ, Medeiros LJ, Elenitoba-Johnson K, et al. Extramedullary myeloid cell tumors. An immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch Pathol Lab Med. 1995;119:790–798.
Miranda RN, Briggs RC, Shults K, et al. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol. 1999;30:1040–1049.
Kawamoto K, Miyoshi H, Yoshida N, et al. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40:1473–1483.
Goyal G, Bartley AC, Patnaik MM, et al. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J. 2017;7:e592.
Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144:219–239.
Magdy M, Abdel Karim N, Eldessouki I, et al. Myeloid sarcoma. Oncol Res Treat. 2019;42:224–229.
O’Malley DP. Benign extramedullary myeloid proliferations. Mod Pathol. 2007;20:405–415.
Dagdas S, Ozet G, Alanoglu G, et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor. Acta Haematol. 2006;116:198–202.
Badr NM, Roberts C, Shaaban AM. Extramedullary haematopoiesis in axillary lymph nodes of breast carcinoma patients receiving neoadjuvant chemotherapy: a potential diagnostic pitfall. Pathobiology. 2019;86:167–172.